Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/23481
Title: Optimal oral cyclosporin dosing with concomitant posaconazole post allogeneic stem cell transplantation.
Austin Authors: Robinson, Danielle H ;Hughes, Charlotte F M;Grigg, Andrew P 
Affiliation: Department of Clinical Haematology, Austin Health, Heidelberg, Victoria, Australia
Olivia Newton-John Cancer Wellness and Research Centre, Austin Health, Heidelberg, Victoria, Australia
Issue Date: Oct-2020
metadata.dc.date: 2020-05-30
Publication information: Leukemia & lymphoma 2020; 61(10): 2448-2452
Abstract: Cyclosporin is an immunosuppressive agent in allogeneic hematopoietic stem cell transplantation and its metabolism is strongly affected by concomitant drugs, including posaconazole which is now extensively used as anti-fungal prophylaxis post-allograft. We undertook a retrospective audit of 29 patients undergoing their first allograft who were receiving posaconazole at the time of transition from intravenous to oral cyclosporin. This group had a median initial oral cyclosporin dose of 2.58 mg/kg bd (range 1.75-3.95) and high incidence of cyclosporin-related toxicity was noted, requiring significant dose reductions such that by day 60 the media dose was 1.60 mg/kg bd (range 0.86-3.33). We subsequently amended our dosing protocol and analyzed a further 20 patients specifying an initial oral cyclosporin dose of 2.25 mg/kg bd and found this had little impact on toxicity or requirement for dose reductions. Starting doses of no greater than 2 mg/kg bd appear optimal to prevent toxicity in allograft recipients receiving concomitant posaconazole.
URI: http://ahro.austin.org.au/austinjspui/handle/1/23481
DOI: 10.1080/10428194.2020.1768381
ORCID: 0000-0001-9809-6757
0000-0003-0384-704X
Journal: Leukemia & lymphoma
PubMed URL: 32476517
Type: Journal Article
Subjects: Transplantation
cyclosporin
drug toxicity
posaconazole
Appears in Collections:Journal articles

Show full item record

Page view(s)

10
checked on Feb 8, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.